NeuroSense Therapeutics Ltd. (NRSN) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 21.6 (OVERSOLD (<32))
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While NRSN currently carries a cautious 38/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.44) and Max Pain ($2.24) forces dealer call-delta covering toward $26.67.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
NeuroSense Therapeutics Ltd. (NRSN) dropped -9.75% to $2.13, trading at 2% of its 52-week range ($1.99 – $25.4). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a biotechnology company developing treatments for neurodegenerative diseases, today announced that its clinical and biomarker findings informin
https://www.sec.gov/Archives/edgar/data/1875091/000121390026112379/ea0309668-6k_neurosense.htm
Gainers Silence Therapeutics (NASDAQ:SLN) stock increased by 125.6% to $19.59 during Monday's regular session. The market value of their outstanding shares is at $581.1 million. SCWorx (NASDAQ:WORX) stock
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company developing treatments for neurodegenerative diseases, today announced that it has filed a patent ap
The application covers the treatment of a broad range of brain injuries, from concussion and mild TBI to moderate and severe TBI, including blast-related injury, as well as their long-term consequences, such as chronic
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on NRSN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for NRSN. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, NeuroSense Therapeutics Ltd. (NRSN) ranks #734 by composite RQD confidence (38/100, grade D-) and #960 by equity capitalization ($4.0M). Within this direct 5-issuer industry benchmark cohort, NRSN leads on earnings valuation at N/A trailing P/E, while ENLV leads on capital efficiency and profitability with -0.6% ROIC and — gross margin. XTLB currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with NRSN at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NRSN
ACTIVE
NeuroSense Therapeutics Ltd. | D- | 38/100 | — | — | -35.0% | -9.75% | $4.0M | Benchmark Subject |
| MDCX Medicus Pharma Ltd. | D- | 35/100 | — | — | -35.0% | -13.31% | $4.1M | /mdcx-vs-nrsn → |
| DRMA Dermata Therapeutics Inc. | D- | 43/100 | — | — | -35.0% | -3.84% | $4.2M | /drma-vs-nrsn → |
| ENLV Enlivex Ltd. | D- | 35/100 | — | — | -0.6% | -2.68% | $3.9M | /enlv-vs-nrsn → |
| XTLB XTL Biopharmaceuticals Ltd. | D | 47/100 | — | — | — | -12.44% | $4.3M | /xtlb-vs-nrsn → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), NeuroSense Therapeutics Ltd. (NRSN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$11.1M, operating cash flow of -$7.7M, and free cash flow of -$7.7M (+24.3% YoY). On the balance sheet, NRSN closed FY2025 with $1.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$11.1M | -$7.7M | -$7.7M | $1.0M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$10.2M | -$10.1M | -$10.1M | $4.6M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$10.1M | -$8.4M | -$8.4M | — | — |
As of 2026-11-01, NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $2.13 (-9.75% 1D, market cap $4.0M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NRSN ranks #734 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NRSN carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MDCX (Medicus Pharma Ltd.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $4.1M) and DRMA (Dermata Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $4.2M). Among the 5-stock peer group, NRSN leads on earnings multiple (N/A) while ENLV leads on capital efficiency (-0.6% ROIC).
Per NRSN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001875091), NeuroSense Therapeutics Ltd. generated $0 in revenue, -$11.1M in net income, and -$7.7M in free cash flow against $1.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
NRSN last traded at $2.13 (-9.75% on volume of 20,578 shares), positioning the stock -60.85% below its 50-day simple moving average ($5.44) and -83.45% below its 200-day simple moving average ($12.87). Across its 52-week range of $1.99 to $25.40, NRSN sits at the 0.6% percentile with a 14-day RSI of 21.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.86 to $2.40).
Why NRSN Stock dropped -9.75% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.